Abstract
Using a murine model of ITP, we have previously demonstrated that both IVIg and a monoclonal antibody which reacts with red cells (TER-119), ameliorates thrombocytopenia. We have also recently demonstrated that passive transfer of IVIg-primed splenic leukocytes can completely recapitulate the effects of standard IVIg therapy in the amelioration of murine ITP, and further showed that CD11c+ dendritic cells were the primary cell mediating IVIg functions (
Nat Med
2006
;12
:688
–692Disclosure: No relevant conflicts of interest to declare.
Author notes
*
Corresponding author
2006, The American Society of Hematology
2006
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal